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Abstract
Oxidative stress enhances inflammation and reduces the effectiveness of corticosteroids,
but the inflammatory signalling pathways induced by oxidants remain ill-defined. Phosphor-
ylation of histone 3 at serine 10 (H3-Pser10) marks out a subset of inflammatory genes for
transcription, several of which are induced in oxidant-associated inflammation. However,
the influence of oxidants or of corticosteroids on this modification remains unknown. We as-
sessed the regulation of H3-Pser10 by oxidants and lipopolysaccharide (LPS) in human
blood monocytes and lung macrophages and the effectiveness of its abolition in controlling
inflammatory gene expression in cells from asthmatic subjects compared to corticosteroids
alone. Both oxidants and LPS promoted the induction of H3-Pser10 which was unaffected
by corticosteroids. The induction of H3-Pser10 was mediated through p38αmitogen-
activated protein kinase (MAPK) and IκB kinase 2 (IKK-2) signalling. Consequently, inhibi-
tors of p38αMAPK or IKK-2 used in combination with dexamethasone were more effective
at controlling inflammatory gene expression from monocytes and lung macrophages from
asthmatic patients than the corticosteroid alone. Therefore, reduction of H3-Pser10 by inhi-
bition of p38αMAPK or of IKK-2 may provide greater anti-inflammatory control than cortico-
steroids alone in oxidant-associated inflammation such as severe asthma.
Introduction
The failure of corticosteroids to control the persistent lung inflammation in severe asthma and
chronic obstructive pulmonary disease (COPD) is widely attributed to oxidative stress [1–3].
Therefore, a detailed understanding of how oxidants impact on inflammatory signalling
is needed.
Histone modifications, such as acetylation, control the recruitment and access of transcrip-
tional complexes to gene promoters [4] and are a major node of inflammatory control. Oxidants
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heighten inflammatory responses, in part, by inactivating histone deacetylase 2 (HDAC2) [5].
This prevents histones at inflammatory gene promoters from being de-acetylated and the in-
flammatory genes silenced. Oxidants also activate stress pathways including kinases such as p38
mitogen-activated protein kinase (MAPK) [6,7], phosphatidylinositol 3-kinase (PI3K) [8,9] and
transcription factors such as NF-κB [10,11]. This, combined with elevated histone acetylation,
culminates in uncontrolled inflammatory transcription which ‘locks’ the cell into a persistent
inflammatory state.
However, histone acetylation is not the sole histone modification that regulates transcrip-
tional control. Phosphorylation of histone 3 at serine 10 (H3-Pser10) is also important in
controlling inflammatory gene transcription [12]. This serves to recruit NF-κB to the gene pro-
moter of a subset of immediate-early pro-inflammatory genes (such as IL-6, CXCL-8 and
CCL-2) and enables subsequent acetylation at lysine residues 9 and 14 [13]. Several pathways
regulate H3-Pser10, including oxidant-sensitive pathways such as the p38 MAPK and IκB Ki-
nase (IKK) pathways [13,14]. Corticosteroids may also influence H3-Pser10 through the induc-
tion of dual specificity MAPK phosphatases (DUSP-1 or MKP-1) which reduces p38 MAPK
activation [15]. Consequently, as oxidants activate p38 MAPK signalling and impair corticoste-
roid function, H3-Pser10 may be involved in the reduced control and chronicity of oxidant-
associated inflammation. However, the impact of oxidants and corticosteroids on the regula-
tion of H3-Pser10 remains unknown.
In this study, we use monocytes from healthy volunteers to examine the impact of oxidative
stress and corticosteroids on the induction of H3-Pser10. Thereafter, in order to study the ef-
fect of oxidant-associated inflammation which is not fully controlled by corticosteroids, we
chose to examine monocytes and lung macrophages from patients with asthma, particularly
severe asthma. The monocytes and macrophages from these patients are less sensitive to the
anti-inflammatory effects of corticosteroids [16,17] which is concordant with poor therapeutic
responsiveness of asthma control by corticosteroid treatment in these patients [18] and there is
evidence of increased oxidative stress [19]. Our aim was to examine whether a reduction in the
induction of H3-Pser10 in the cells from the asthmatic subjects produced a greater control of
inflammatory cytokine expression than a corticosteroid alone.
Our findings indicate that oxidants induce H3-Pser10 which was not inhibited by dexa-
methasone and reducing H3-Pser10 using the selective p38αMAPK inhibitor, SB239063, and
the IKK-2 inhibitor, TPCA-1, is more effective at controlling the expression of inflammatory
mediators in cells from asthmatic patients than corticosteroids alone.
Materials and Methods
Subjects
Healthy volunteers had no history of respiratory disease had normal spirometric results. Pa-
tients with severe asthma were prospectively recruited from the Severe Asthma clinic at the
Royal Brompton Hospital, London. Patients with severe asthma needed either continuous or
near-continuous oral corticosteroids, high-dose inhaled corticosteroids, or both to achieve a
level of mild-to-moderate persistent asthma, and by 2 or more minor criteria (Table 1) [20].
Patients with non-severe asthma had controlled asthma while using up to 2,000 μg/day or
equivalent of inhaled beclomethasone. Current smokers and ex-smokers of greater than 5
pack-years of smoking were excluded. Asthmatic subjects underwent fiberoptic bronchoscopy
during which bronchoalveolar lavage was performed and lung macrophages were obtained. All
the subjects were free from upper respiratory tract infections and acute exacerbations within 3
months before bronchoscopy. All patients provided written informed consent to participate in
Oxidant-Mediated Histone Phosphorylation
PLOS ONE | DOI:10.1371/journal.pone.0124961 April 23, 2015 2 / 12
this study, which was approved by the Brompton, Harefield and NHLI Research Ethics Com-
mittee (08/H0708/29).
Isolation of peripheral blood monocytes and alveolar macrophages
Peripheral blood mononuclear cells (PBMCs) were isolated from the peripheral blood of nor-
mal healthy and asthmatic subjects using discontinuous Percoll gradients. The monocytes were
purified (>95%) using the Monocyte Isolation kit II (Miltenyi Biotech). Alveolar macrophages
(AMs) were isolated from the bronchoalveolar lavage (BAL) from non-severe asthmatic sub-
jects and severe asthmatic subjects (Table 1) by selective adhesion yielding macrophage purity
of>97%. Cells were cultured in phenol red free RPMI 1640 with 1% autologus serum, 5% L-
glutamine and 5% penicillin/streptomycin (Gibco).
Reagents
The kinase inhibitors SB239063 (a p38αMAPK inhibitor), TPCA-1(an IKK-2 inhibitor) were
purchased fromMerck Biosciences. Dexamethasone, hydrogen peroxide (H2O2) and pyocya-
nin were purchased from Sigma and 1,2,3,4-Oxatriazolium, 5-amino-3-(3,4-dichlorophenyl)-
chloride (GEA 3162) was purchased from Calbiochem. The anti-Histone H3 P-Ser10 and anti-
Histone H3 (Millipore) antibodies were purchased fromMillipore and the anti-phospho-p38
MAPK, anti-p38 MAPK anti-phospho-IKK1/2 and anti-IKK-2 were purchased from Cell Sig-
naling Technology.
Cell treatment
Monocytes and AMs were cultured overnight with inhibitors added 1 hour prior to stimula-
tion. The cells were then stimulated with LPS (Sigma), or oxidants as detailed in the figures.
The expression of selected proteins was knocked down by siRNAs (Applied Biosystems) using
lipofectamine 2000 (Invitrogen). The siRNAs against p38αMAPK, MSK-1, MSK-2, IKK-1 and
IKK-2 were introduced to the cells as per the manufacturer’s instructions and the effective
knockdown of protein levels was observed 72h after transfection as assessed by Western blot-
ting for the respective target protein levels.
Western Blotting
Cytosolic extracts were isolated using a hypotonic extraction buffer; 50mM Tris pH 8.0,
2mM EDTA pH 8, 0.1% NP40, 10% Glycerol, protease inhibitors (Merck Biosciences) and
Table 1. Characteristics of non-severe and severe asthmatic subjects.
Non-severe asthmatics (n = 11) Severe asthmatics (n = 10)
Sex (M:F) 6:5 2:8
Age (years) 38.8 ± 13.4 48.2 ± 13.6
Duration of Asthma (years) 29.2 ± 15.3 27.3 ± 10.7
FEV1 (% predicted) 84.6 ± 11.9 74.3 ± 26.4
Bronchodilator response (% increase in FEV1) 14.8 ± 7.6 25.2 ± 21.1
Log PC20 methacholine (mg/ml) 1.2 ± 1.9 1.1 ± 0.5
Prednisolone dose (mg/day) none 11.1 ± 12.9a
Beclomethasone Dipropionate equivalent (μg/day) 677.7 ± 463.1 1362.5 ± 483.8
a6 severe asthmatic subjects were on oral prednisolone at the time of the study. Data shown as mean ± SEM.
doi:10.1371/journal.pone.0124961.t001
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phosphatase inhibitors (Roche Applied Sciences). Nuclear extracts were isolated using a 1%
SDS lysis buffer; 50mM Tris pH 8.0, 5mM EDTA pH 8, 1% SDS, protease inhibitors (Merck)
and phosphatase inhibitors (Roche). Samples were run on 4–12% Bis-Tris gels (Invitrogen)
and transferred onto Optitran BA-S 83 nitrocellulose (Whatman; GE Heathcare Life Sciences).
Blots were developed using ECL (GE Healthcare Life Sciences).
Chromatin Immunoprecipitation (ChIP) Assay
ChIP assays were performed on 1x106 cells using EZ-Magna ChIP kits (Millipore) as per the
manufacturer’s instructions. Sonication was performed with a MSE Soniprep 150 (MSE UK
Ltd, London, UK) using 9 x 10 second bursts at 10 amplitude microns with 60 seconds on ice
between pulses. Immunoprecipitation of H3-Pser10 was performed overnight with the ChI-
PAb+ anti-H3-Pser10 antibody (Millipore). qRT-PCR was performed using SYBR Green Fas-
tmix (Applied Biosystems) with primers designed around NF-κB promoters upstream of the
CXCL-8, IL-6, TNFα and CCL-2 genes (synthesised by Eurofins). CXCL-8: 5’-GGGCCAT
CAGTTGCAAATC-3’ and 5’-TTCCTTCCGGTGGTTTCTTC-3’. IL-6; 5’-GCCCAGCTAT
GAACTCCTTCTC-3’ and 5’-CTGGCAGTTCCAGGGCTAAG-3’. TNFα; 5’-GAAGGTG
CAGGGCCCAC-3’ and 5’-CTTGGTGGAGAAACCCAT-3’. CCL-2; 5’-GCTCCAGC
CAAATGCATTCT-3’ and 5’-TGAGGAGGCAGCTTTGGAAGT-3’. qRT-PCR was performed
using a Applied Biosystems 7500 Fast Real-Time PCR System (Applied Biosystems).
Real Time RT-PCR
RNA extractions were performed using RNeasy kits (Qiagen) according to the manufacturer’s
instructions. RNA was quantified using a nanodrop (Thermo Scientific) and 2μg of RNA was
transcribed into cDNA using; 10U AMV RTase, 40U RNAsin, 25ng/ml Hexamer primer,
1mM 4xdNTPs (Promega). qRT-PCR was performed using 5μl of cDNA with TaqMan Gene
Expression master mix (Applied Biosystems) and pre-designed Taqman probes for IL-6,
CXCL-8, TNFα, CCL-2 and GNB2L (Applied Biosystems) according to the manufacturer’s in-
structions using a Corbett Rotor-Gene Thermocycler (Corbett Research Ltd).
Statistical analysis
Statistical analysis was performed by one-way ANOVA with Tukeys post-hoc test using
GraphPad Prism 5 software (GraphPad Software Inc). Differences were considered significant
at P< 0.05.
Results
Oxidative stress induces a sustained induction of H3-Pser10 and
augments LPS induce H3-Pser10 in monocytes
LPS and both exogenously-derived oxidants (via H2O2 and GEA, a superoxide, nitric oxide
and peroxynitrite generator) and endogenously-derived oxidants (via pyocyanin, a superoxide
generator via the mitochondria) induced H3-Pser10 in human blood monocytes from healthy
volunteers (Fig 1). The induction by LPS was relatively transient, with a reduction by 4–8h (Fig
1A and 1B). In contrast, the oxidant-mediated by H2O2 was more prolonged than that elicited
by LPS, lasting up to 24h (Fig 1E). In addition, low concentrations of LPS (<1ng/ml) mediated
a greater induction of H3-Pser10 in the presence of H2O2 (Fig 1F).
Oxidant-Mediated Histone Phosphorylation
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Oxidant induction of H3-Pser10 in monocytes is mediated by p38α
MAPK via MSK1 signalling and IKK-2 which is unaffected by
corticosteroids
The induction of H3-Pser10 by both LPS and H2O2 was impaired by selective inhibition of p38
MAPKα using SB239063 and IKK-2 using TPCA-1 in human blood monocytes from healthy
volunteers (Fig 2A and 2B). SB239063 is selective for the p38 α and β isoforms (IC50 = 44nM)
with ~200 fold selectivity compared to other MAP Kinases and no effects on the γ and δ p38
MAPK isoforms. The α p38 MAPK isoform is highly expressed in monocytes and macro-
phages, whilst the protein expression of the β,γ and δ isoforms are very low to undetectable
[21]. Therefore the effects of SB239063 in the monocytes are mediated through the inhibition
Fig 1. Induction of H3-Pser10 by LPS and oxidants. Panels A-F show the induction of H3-Pser10
measured by western blot analysis in blood monocytes from a normal healthy subject, with the dose-
dependent effect of LPS (A), time-course (B), the comparative effect of LPS and oxidants H2O2, GEA and
pyocyanin (C), dose-dependency and time-course effect of H2O2 (D, E) and the interaction of H2O2 and LPS
(F).
doi:10.1371/journal.pone.0124961.g001
Fig 2. Induction of H3-Pser-10 is dependent in p38αMAPK and IKK-2 signalling. Panel A shows the
expression of H3-Pser10 measured by western blot from blood monocytes from a healthy normal subject
induced by H2O2 and LPS, and the effect of the p38αMAPK inhibitor SB239063 and the IKK-2 inhibitor
TPCA-1. Panel B shows the concentration dependent reduction of LPS-induced H3-Pser10 expression by
SB239063 and TPCA-1. Panel C shows the reduction of LPS-induced H3-Pser10 by siRNA knockdown of
p38αMAPK, MSK-1 and IKK-2 protein expression but not by knockdown of MSK-2 or IKK-1
protein expression.
doi:10.1371/journal.pone.0124961.g002
Oxidant-Mediated Histone Phosphorylation
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of the p38αMAPK isoform. The IKK inhibitor TPCA-1 is relatively selective for the IKK-2 iso-
form (IC50 = 17.9nM), exhibiting a 22-fold selectivity over the IKK-1 isoform (400nM).
Phosphorylation of nuclear proteins via the 38αMAPK pathways may be mediated directly
or through downstream signalling mediators including the mitogen- and stress-activated pro-
tein kinases 1 and 2 (MSK1/2). Selective knockdown of p38αMAPK and MSK-1 but not MSK-
2 protein levels using siRNA reduced the LPS-mediated induction of H3-Pser10 confirming
the involvement of p38αMAPK and MSK-1 (Fig 2C). IKK-1 may also be involved in the regu-
lation of H3-Pser10 [14]. However, selective knock-down of IKK-2 but not IKK-1 protein re-
duced the LPS-mediated induction of H3-Pser10, confirming the involvement of IKK-2 in the
induction of H3-Pser10 by LPS (Fig 2C). Both LPS and H2O2 induced the phosphorylation of
p38αMAPK, with a more sustained elicitation from H2O2 (Fig 3A–3C). IKK-2 phosphoryla-
tion was only induced by LPS with H2O2 having no effect (Fig 3A and 3B)
Corticosteroids can modulate p38αMAPK signalling through the induction of DUSP-1/
MSK-1. However, dexamethasone, budesonide and prednisolone had no effect on the induc-
tion of H3-Pser10 by H2O2 in human blood monocytes from healthy volunteers (Fig 4A).
Dexamethasone had no effect on the induction of H3-Pser10 mediated by LPS or by LPS in
Fig 3. Induction of p38 MAPKα is prolonged by oxidants. Panels A and B show the phosphorylation of
p38αMAPK and IKK-2 by LPS and by H2O2 respectively onWestern blot of blood monocytes from a healthy
subject. Panel C shows the persistence of p38αMAPK phosphorylation after 8hours after exposure to LPS,
H2O2 or a combination of LPS and H2O2.
doi:10.1371/journal.pone.0124961.g003
Fig 4. H3-Pser10 induction is associated with inflammatory gene induction and is sensitive to p38α
MAPK and IKK2 inhibition but not by corticosteroid. Panels A to C show western blot analysis of
H3-Pser10 expression of blood monocytes from a normal subject exposed to H2O2 (A), LPS (B) or to both
H2O2 and LPs (C) in the presence of dexamethasone (DEX), budesonide (BUD) and prednisolone (PRED)
Panels D-G show the mean data of the effect of SB239063, TPCA-1 and dexamethasone on the association
of at the gene promoter of IL-6 (D), CXCL-8 (E), TNFα (F) and CCL-2 (G) with H3-Pser10 as assessed by
ChIP of H3-Pser10 followed by qRT-PCR for the respective gene promoter in alveolar macrophages from
non-severe and severe asthmatic subjects. Data is presented as the mean ± SEM. Severe asthmatics n = 5,
non-severe asthmatics n = 11. * p<0.05, **p<0.01,*** p<0.001 as compared to LPS treated non-severe
asthmatics; #p<0.05, ##p<0.01 as compared to LPS-treated severe asthmatics.
doi:10.1371/journal.pone.0124961.g004
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combination with H2O2 (Fig 4B and 4C), with only a supraphysiological (10μM) concentration
of dexamethasone causing any reduction in H3-Pser10.
LPS induces H3-Pser10 at the promoter region of pro-inflammatory
genes which is abolished by inhibition of p38αMAPK or of IKK-2 but not
by CS treatment
LPS induced H3-Pser10 at the promoter region of IL-6, CXCL-8, and CCL-2 genes in AMs
from both non-severe and severe asthmatics (Fig 4D–4G). There was very little increase in
the association of the TNFα gene and H3-Pser10 after LPS stimulation (Fig 4F) which is consis-
tent with previous data suggesting that LPS-induced TNFα expression is largely H3-Pser10-
independent [13]. Consistent with the failure of dexamethasone to reduce an induction of
H3-Pser10 (Fig 4A–4C), dexamethasone treatment had no significant impact on the associa-
tion of any of these genes with H3-Pser10. Inhibition of p38αMAPK using SB239063 signifi-
cantly reduced the association of IL-6, CXCL-8 and CCL-2 with H3-Pser10 (Fig 4D, 4E and
4G). Similarly, inhibition of IKK-2 using TPCA-1 also reduced the association of IL-6, CXCL-8
and CCL-2 with H3-Pser10 (Fig 4D, 4E and 4G). The reduction in H3-Pser10 at the gene pro-
moters by both SB23063 and TPCA-1 was comparable between non-severe and severe asth-
matic AMs and there was no further effect by co-treatment with dexamethasone.
Inhibition of p38αMAPKα or IKK-2 combined with CS suppresses the
expression of pro-inflammatory mediators which are not fully
suppressed by CS alone
Monocytes from both non-severe and severe asthmatics expressed IL-6, TNFα, CCL-2 and
CXCL-8 mRNA which was increased by exposure to LPS (Fig 5A and 5B). SB239063 elicited a
comparable inhibition in the induction of IL-6, TNFα and CXCL-8 mRNA in monocytes from
both non-severe and severe asthmatics as compared to dexamethasone alone (Fig 5C–5F).
However, the combination of SB239063 and dexamethasone was significantly more effective at
Fig 5. Inhibition of p38αMAPK or IKK-2 in combination with corticosteroids is more effective at
reducing LPS induced inflammatory gene expression in asthmatic patients than corticosteroids
alone. Panels A to B show the mean mRNA expression determined by real time qRT-PCR of IL-6, TNFα,
CCL-2, and CXCL-8 in monocytes from non-severe and severe asthmatic subjects at baseline (A) or after
exposure to LPS (B). Panels C to F show the mean mRNA expression of IL-6 (C), TNFα (D), CCL-2 (E), and
CXCL-8 (F) in monocytes from non-severe and severe asthmatic subjects after exposure to LPS in the
presence of dexamethasone (DEX), SB239063 or TPCA-1 or a combination of dexamethasone and either
SB239063 or TPCA-1. Data is presented as mean ± SEM. Severe asthmatics n = 8, non-severe asthmatics
n = 8. *p<0.05, **p<0.01, ***p<0.001 as compared to LPS-treated severe asthmatics; #p<0.05, ##p<0.01,
###p<0.001 as compared to LPS-treated non-severe asthmatics.
doi:10.1371/journal.pone.0124961.g005
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reducing the induction of IL-6 mRNA expression in both non-severe and severe asthmatics
and TNFαmRNA expression in non-severe asthmatics compared to dexamethasone alone.
TPCA-1 was significantly more effective at reducing LPS-induction of IL-6 and TNFα in
monocytes from non-severe and severe asthmatics compared to dexamethasone (Fig 5C and
5D). TPCA-1 co-treatment with dexamethasone was more effective at reducing the induction of
IL-6 and TNFαmRNA expression compared to either treatment alone and also significantly re-
duced the mRNA expression of CCL-2 compared to dexamethasone treatment alone (Fig 5C–
5F). Neither SB239063 nor TPCA-1 alone reduced the induction of CXCL-8 mRNA in either
non-severe or severe asthmatic monocytes, even when combined with dexamethasone (Fig 5F).
Discussion
We have shown that both oxidative stress and LPS induced H3-Pser10 in human blood mono-
cytes through the activation of p38αMAPK which was unaffected by corticosteroids. LPS also
induced H3-Pser10 through the activation of IKK-2 and inhibition of either p38αMAPK or
IKK-2 was more effective at controlling inflammatory gene expression in monocytes and AMs
from asthmatic subjects than a corticosteroid alone.
Although LPS and oxidative stress both induced H3-Pser10, their pattern of induction dif-
fers markedly. LPS induced a rapid and transient phosphorylation which is consistent with its
role in the transcription of immediate early inflammatory genes [13] while the induction by
oxidants was more prolonged, lasting up to 24 hours. This may reflect an oxidant-mediated
dysregulation of the pathways that influences H3-Pser10. Indeed, oxidative stress activates a
number of stress pathways that regulate H3-Pser10 including the p38αMAPK pathway [6,7],
which in turn induces immediate-early (IE) gene transcription through activation of one of
p38 MAPKs downstream effectors, MSK-1 [22,23]. Consistent with this, both the LPS and the
oxidant induction of H3-Pser10 was abolished by selective inhibition of p38αMAPK or selec-
tive knockdown of MSK-1. The induction of H3-Pser10 by LPS also involved the activation of
IKK-2 which could be blocked using the IKK-2 inhibitor TPCA-1 or selective knockdown
of IKK-2 using siRNA; however, the involvement of this pathway was absent in the oxidant-
mediated induction suggesting that distinct pathways regulate the induction of immediate-
early genes which are stimulus dependant.
Consistent with the prolonged induction of H3-Pser10, the oxidant-mediated induction of
p38 MAPK was also prolonged compared to LPS which may account, in part, for the sustained
phosphorylation of H3. Oxidative stress can also reduce phosphatase activity through direct
covalent modification [24]. Therefore, impairment in phosphatase activity may also directly
sustain H3-Pser10 by reducing the rate of its de-phosphorylation. However the mechanism of
this sustained induction remains unclear and further detailed molecular studies are needed to
fully elucidate the mechanism.
Another interesting observation was the ability of oxidants also to sensitise the induction of
H3-Pser10 by LPS. This suggests that the induction of H3-Pser10 by inflammatory stimuli
such as bacterial products may be heightened in the presence of oxidative stress, which in
turn could contribute to the heightened inflammatory response seen in oxidant associated-
inflammation. Therefore, anti-inflammatory therapies that control H3-Pser10 as part for their
action may be beneficial in oxidant associated-inflammation.
Corticosteroids are powerful anti-inflammatory drugs which are widely used to treat persis-
tent inflammation in chronic diseases such as asthma. Part for their action is mediated through
the expression of anti-inflammatory genes such as the phosphatase DUSP-1/MKP-1 [25]
which supresses p38 MAPK signalling [15]. Consequently, part of the anti-inflammatory ac-
tion of a corticosteroid may be mediated through an induction of DUSP-1/MKP-1 which in
Oxidant-Mediated Histone Phosphorylation
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turn prevents a prolonged induction of H3-Pser10. However, corticosteroids failed to inhibit
the induction of H3-Pser10 by either LPS or oxidative stress, suggesting that modulation of
H3-Pser10 is not one of their major anti-inflammatory actions. Therefore, where an inflamma-
tory microenvironment facilitates an uncontrolled production of key inflammatory mediators,
driven in part by the induction of H3-Pser10, a firmer control of the inflammation may be de-
sirable by combining corticosteroid treatment with one whose actions include a direct reduc-
tion of H3-Pser10.
Indeed, although corticosteroids are widely effective anti-inflammatory drugs they are less ef-
fective at controlling oxidant-associated chronic inflammation, such as in the lungs of severe
asthmatic patients [2,17,26]. Interestingly, both p38αMAPK and IKK-2 activities are elevated in
severe asthma [27,28], as are a number of H3-Pser10-regulated genes including IL-6, CCL-2 and
CXCL-8 [16,17]. Therefore, direct inhibition of H3-Pser10 through modulation of p38αMAPK
or IKK-2 is potentially a novel therapeutic target to improve inflammatory control in severe
asthma. Indeed, selective inhibitors of p38αMAPK and IKK-2 have potent anti-inflammatory
properties [21,29] and our studies also suggest that inhibition of p38αMAPK improves the re-
duced corticosteroid responsiveness in alveolar macrophages from severe asthmatics [30].
In this study, inhibition of p38αMAPK or of IKK-2 but not dexamethasone reduced the in-
duction of H3-Pser10 at the gene promoters of IL-6, CCL-2 and CXCL-8 in alveolar macro-
phages from severe asthmatic patients. This was consistent with the failure of dexamethasone to
reduce the induction of H3-ser10 mediated by LPS or oxidants. Furthermore, both inhibition of
p38αMAPK and IKK-2 was more effective at reducing LPS-induced IL-6, TNFα, CCL-2 and
CXCL-8 in monocytes from asthmatic subjects than corticosteroid alone, with a greater inhibi-
tion of IL-6, TNFα and CCL-2 when the inhibitors were used in combination with dexametha-
sone. These data support the notion that abolition of H3-Pser10 by inhibition of either p38α
MAPK or IKK-2 may provide a more effective control of some inflammatory genes in asthma
than corticosteroids alone. It is of course important to consider that inhibiting p38αMAPK and
IKK-2 has a number of major anti-inflammatory effects, particularly in the inhibition of the ac-
tivation of NF-κB (Fig 6). These will be significant factors in their functional effect in reducing
inflammatory mediator expression. Inhibition of H3-Pser10 should therefore be viewed as a
mechanism that both reduces the activation of NF-κB and its targeting to immediate-early in-
flammatory genes which are otherwise poorly controlled by corticosteroids alone patients with
severe asthma.
Fig 6. Diagram of the anti-inflammatory actions derived from the inhibition of p38αMAPK and IKK-2
throughmodulation of NF-κB activation and its subsequent association with inflammatory genes.
Inhibition of either p38αMAPK or of IKK-2 reduces the activation of NF-κB and reduces H3-Pser10 which
marks serves to flag selected immediate-early inflammatory gene for NF-κB-mediated transcription, thus
reducing their expression. In addition, inhibition of p38αMAPKmay increase the effectiveness of
corticosteroids in asthmatic patient macrophages and both inhibitors of IKK-2 and p38αMAPKmay be
effective in oxidant-associated inflammation.
doi:10.1371/journal.pone.0124961.g006
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In addition, it is critical that potential new therapies in diseases with oxidant-associated in-
flammation, such as in severe asthma [19], maintain their anti-inflammatory action in an oxi-
dative microenvironment. This is evident in the case of corticosteroids whose reduction in
effectiveness in severe asthma and other oxidant-associated diseases such as chronic obstruc-
tive pulmonary disease (COPD) is directly related to oxidants altering cellular and protein
functions [1]. Inhibitors of both p38αMAPK and of IKK-2 have been shown to be effective in
in vivomodels of oxidative stress [31,32], however other studies suggest that IKK-2 inhibitors
may not effective [33]. This serves to highlight the importance of identifying which molecules
retain their effectiveness in oxidant-associated inflammation using a number of models.
In summary, we show that oxidants can promote a sustained induction of H3-Pser10 which
in turn may contribute to the enhanced inflammation in oxidant-associated disease. This in-
duction of H3-Pser10 is unaffected by corticosteroids and therefore our data also suggests that
a reduction in H3-Pser10 through the inhibition of either p38αMAPK or IKK-2 in combina-
tion with corticosteroids may be significantly more effective at reducing the expression of key
inflammatory mediators in oxidant-associated disease than by corticosteroids alone. Both in-
hibitors of p38 MAPK and IKK are in clinical development; however, detailed studies will be
needed to assess if these therapies maintain their anti-inflammatory action in diseases such as
severe asthma and COPD.
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